Although most NSCLC cases harboring EGFR mutations respond to initial therapy with first-generation tyrosine kinase inhibitors (TKIs), including erlotinib and gefitinib 6, 7, many of them develop TKI resistance within a year after the initiation of treatment 8. This evidence concerns the gene EGFR and non-small cell lung carcinoma.